Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -93.2%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $7M | $6M | $4M | $5M | $36M | $60M | — | — | — | — |
| Enterprise Value | $2M | $6M | $2M | $225197 | $-1839547 | $16M | $41M | — | — | — | — |
| P/E Ratio → | -0.70 | — | 0.83 | — | — | — | — | — | — | — | — |
| P/S Ratio | 116.54 | 240.83 | 14.16 | 2.32 | 3.34 | 12.27 | 16.49 | — | — | — | — |
| P/B Ratio | 0.95 | 1.51 | 0.59 | 3.27 | 0.97 | 2.11 | 4.08 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 187.26 | 6.00 | 0.14 | -1.29 | 5.41 | 11.48 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 91.7% | 97.6% | 94.0% | — |
| Operating Margin | -9390.8% | -9390.8% | -681.8% | -139.1% | -741.0% | -531.7% | -338.9% | -528.6% | -23.6% | -647.1% | -18059.9% |
| Net Profit Margin | -22448.4% | -22448.4% | 1746.0% | -654.5% | -1462.6% | -526.4% | -355.9% | -535.0% | -27.2% | -656.2% | -18174.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | -93.2% | 130.4% | -348.5% | -190.5% | -97.3% | -64.1% | -45.6% | -8.1% | -420.3% | -334.5% |
| ROA | -78.9% | -78.9% | 92.1% | -163.4% | -135.0% | -71.9% | -48.3% | -39.3% | -7.3% | -138.2% | -137.7% |
| ROIC | -44.3% | -44.3% | -103.3% | — | — | — | — | — | — | — | — |
| ROCE | -37.4% | -37.4% | -47.4% | -66.5% | -90.1% | -88.7% | -55.8% | -43.4% | -6.9% | -320.4% | -273.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.00 | 0.30 | 0.08 | 0.03 | 0.04 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.34 | -3.07 | -1.34 | -1.18 | -1.24 | -1.21 | -1.06 | -1.93 | -6.48 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | -23.91 | — | — |
| Interest Coverage | -2825.35 | -2825.35 | -1383.08 | -115.53 | -220.38 | -242.63 | -184.01 | -114.01 | -6.86 | -71.34 | -453.85 |
Net cash position: cash ($2M) exceeds total debt ($34727)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.40 | 1.40 | 4.42 | 1.46 | 2.39 | 5.31 | 5.38 | 5.70 | 18.06 | 2.07 | 1.33 |
| Quick Ratio | 1.40 | 1.40 | 4.42 | 1.46 | 2.39 | 5.31 | 5.34 | 5.70 | 18.06 | 2.07 | 1.33 |
| Cash Ratio | 1.37 | 1.37 | 4.17 | 1.34 | 2.12 | 4.96 | 5.18 | 5.55 | 17.86 | 1.75 | 1.13 |
| Asset Turnover | — | 0.00 | 0.04 | 0.35 | 0.17 | 0.13 | 0.18 | 0.08 | 0.14 | 0.16 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 244.89 | 14.01 | 34.23 | 153.53 | 40.60 | 6.91 | 15.59 | 16.49 | 221.88 | 4649.08 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 120.0% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $935000 | $817606 | $619230 | $376540 | $284330 | $222348 | $220235 | $194110 | $107845 | $95102 |
Critical liquidity and funding
According to recent market data, ADXN trades at a price-to-sales ratio of 118.09, a figure that appears disconnected from fundamental performance and likely reflects speculative option-value pricing rather than any underlying earnings power or predictable growth trajectory within the competitive CNS biotechnology landscape.
The extreme P/S multiple suggests that investors are pricing the company as a binary outcome play rather than a traditional operating business. Given the lack of recurring revenue, this valuation is highly sensitive to clinical trial readouts and may contract sharply if the company is forced to raise capital through dilutive equity offerings.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -12.8% in 2026Q1, which indicates that the firm is currently destroying shareholder value by deploying capital into research programs that have yet to demonstrate a path toward commercial viability or positive economic returns.
The negative ROIC trend highlights the inefficiency of the current R&D-heavy model, where capital is consumed by clinical infrastructure without generating offsetting returns. This persistent decay warrants investigation into whether the company's proprietary GPCR platform can ever achieve the scale necessary to overcome its high fixed-cost base.
Based on the most recent quarterly data, the current ratio has deteriorated to 0.97, down from a peak of 4.97 in 2024Q2, indicating that the company's ability to cover short-term obligations is increasingly compromised as cash reserves dwindle to a precarious level.
A current ratio below 1.0 suggests that the company may struggle to meet its immediate operational liabilities without external intervention. Investors should monitor this metric closely, as it serves as a primary indicator of the firm's proximity to a potential liquidity crisis or the necessity for emergency financing.
Data from recent filings indicates that the use of standard net margin or P/E ratios is fundamentally misapplied to ADXN, as these metrics obscure the reality that the firm is a pre-revenue development entity where accounting losses are a function of R&D investment rather than operational failure.
Analysts should instead focus on cash burn rates and the remaining operational runway, as GAAP profitability is irrelevant for a company in this stage of the drug development lifecycle. Relying on traditional earnings-based ratios may lead to an incorrect assessment of the company's true financial health and survival prospects.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADXN stock.
Addex Therapeutics Ltd's current P/E ratio is -0.7x. The historical average is 0.8x.
Addex Therapeutics Ltd's return on equity (ROE) is -93.2%. The historical average is -113.1%.
Based on historical data, Addex Therapeutics Ltd is trading at a P/E of -0.7x. Compare with industry peers and growth rates for a complete picture.
Addex Therapeutics Ltd has 100.0% gross margin and -9390.8% operating margin.